New date for publication of Vigmed Holding AB Interim Report for 1 January – 31 March 2017

The Board of Directors of Vigmed Holding AB have decided to postpone the publication of the Interim Report for 1 January – 31 March to May 30, 2017.

The report was planned to be published May 11, 2017.


For further information contact:
Chairman of the Board Sten Dahlborg, +46 708-369 419
CEO Henrik Olsen, +46 763-497 364

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor.Additional information about the company can be found on Vigmed’s website:   www.vigmed.com/investor

 

Tags:

About Us

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and the company has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information can be found on Vigmed’s home page: www.vigmed.com

Subscribe

Documents & Links